title: Variation in management of early breast cancer in the Netherlands, 2003-2006.
abstract: BACKGROUND
  To describe variation in staging and primary treatment by hospital characteristics including type and volume and region in patients with early breast cancer (BC) in the Netherlands, 2003-2006 after completion of national guidelines in 2002.
  
  
  METHODS
  All patients newly diagnosed with invasive BC in 2003-2006 and recorded in the Netherlands Cancer Registry were included (n = 51 354). Multivariable logistic regression analyses examined the influence of patient and hospital characteristics, also by region, on type of breast surgery, axillary lymph node dissection (ALND), sentinel node procedure (SNP), and adjuvant irradiation and/or systemic treatment.
  
  
  RESULTS
  Patients <40 years more often underwent breast conserving surgery (BCS) in general hospitals (OR 1.4 (95%CI 1.1-1.5)) than in teaching and academic hospitals, whereas patients of 40-69 years less often received BCS in an academic hospital (OR 0.9 (95%CI 0.8-1.0)) than in teaching hospitals. Patients with pT1-2N0 cancer more often underwent primary ALND in a general hospital than in a larger teaching or academic hospital. Type of hospital did not seem to affect utilization of adjuvant systemic therapy, but patient age and tumour size and grade did. Over time, patients more often received SNP, BCS, and adjuvant systemic therapy, primary ALND being on the decline, but with substantial regional variation between geographic regions.
  
  
  CONCLUSIONS
  With detailed evidence-based national guidelines since 2002 the considerable regional and hospital variation in staging procedures and primary treatment among newly diagnosed patients with early breast cancer in the Netherlands decreased markedly, suggesting the presence of late adaptors rather than specific hospital characteristics.
authors.affiliation: Comprehensive Cancer Centre South, Eindhoven, The Netherlands.
authors.forename: L N
authors.initials: LN
authors.lastname: van Steenbergen
authors.forename: L V
authors.initials: LV
authors.lastname: van de Poll-Franse
authors.forename: M W J M
authors.initials: MW
authors.lastname: Wouters
authors.forename: M L E A
authors.initials: ML
authors.lastname: Jansen-Landheer
authors.forename: J W W
authors.initials: JW
authors.lastname: Coebergh
authors.forename: H
authors.initials: H
authors.lastname: Struikmans
authors.forename: V C G
authors.initials: VC
authors.lastname: Tjan-Heijnen
authors.forename: C J H
authors.initials: CJ
authors.lastname: van de Velde
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001365:Axilla; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006761:Hospitals / Q000706:statistics & numerical data*; D006801:Humans; D016015:Logistic Models; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009367:Neoplasm Staging; D009426:Netherlands / Q000453:epidemiology; D018714:Radiotherapy, Adjuvant; D012042:Registries; D021701:Sentinel Lymph Node Biopsy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents